SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and break below a major psychological level have dominated discussion, with traders pointing to leveraged-position liquidations as adding to the pressure. The community is split between expectations of further downside amid risk-off and rate concerns and calls to buy an oversold dip.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas is drawing attention as its Phase 3 REGAL trial of GPS reaches final analysis after the 80th event, with topline results expected in November. Traders celebrated an after-hours jump and speculated about a data leak or short covering, while skeptics stressed that the results are still unknown and managements positive language does not establish success.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupted Outlook, Teams, Copilot and other services, prompting complaints about business disruption and concern that the incident could damage trust. Traders debated whether it was a technical failure or a cyberattack, though hacking claims remained speculation, and many questioned why the shares held up amid the disruption.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs confirmed decision to remove Strategy from its indexes is raising concerns about passive-fund selling and pressure on the stock, while Bitcoins decline is adding to the weakness. Traders disagree on whether the index impact is already priced in, with bearish forced-selling concerns countered by dip-buying and hopes for a rebound.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

IBRX is drawing attention after a sharp selloff tied to a Q3 revenue miss and the lack of detailed guidance, with traders debating cash burn, possible dilution, and managements communication. Optimism about the BCG-naive trial results, a planned FDA filing, expanded Anktiva access, and sepsis studies is countered by concern that commercial growth may not keep pace with expectations.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.03439229 USD and is down -2.16 over the last 24 hours. It is currently trading on 1895 active market(s) with $1,786,076,895.36 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

A broad crypto selloff has XRP sliding toward key support, with traders pointing to Bitcoin-led market weakness, inflation and rate-hike concerns, and leveraged liquidations. The community is split between holders accumulating the dip and bearish traders warning of more downside, while some also cite Ripple-related token supply and fading regulatory hopes.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

FDA discussions over assay refinement pushed Candels planned prostate-cancer BLA filing to mid-2027, and traders are also concerned about potential dilution. The community is split between viewing this as a manufacturing and regulatory delay rather than a setback to the clinical data, and questioning managements credibility and execution.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,212,724.47747979. The last known price of Ethereum is 2,011.23339821 USD and is down -2.26 over the last 24 hours. It is currently trading on 14326 active market(s) with $10,433,558,649.69 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is drawing attention amid a sharp crypto-market selloff, with traders pointing to inflation and hawkish rate expectations, Bitcoin weakness, and leveraged-position liquidations as pressure on prices. The community is divided between bearish calls for further losses and buyers treating the decline as an oversold opportunity, while key support levels are closely watched.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs departure as CEO amid reports of a personal scandal has sparked concern about Nvidias leadership transition, with Colette Kress serving as interim CEO. Traders are divided between fears that the company may struggle without Huang and views that its business can withstand the change, with some buying the selloff ahead of earnings.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoins sharp decline and broader weakness in crypto-linked stocks are weighing on Coinbase, with traders focused on its repeated lows and whether the selloff will continue. The discussion is predominantly bearish, though some see the stock as oversold or holding support and expect a rebound if crypto stabilizes.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will HALO's Partner Royalties Drive Growth for the Rest of 2026?

Halozyme's royalty revenues surged 45.8% in the first nine months of 2026, prompting higher guidance.

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why 

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up

TG Therapeutics beats Q3 earnings and revenue estimates as Briumvi demand accelerates, shares rise 5.9%, and 2026 revenue guidance climbs to $1 billion.

NVIDIA Governance Woes: 3 Areas to Buy From Amid AI Market Slump

NVIDIA's controversy and AI market correction prompt investors to explore healthcare, consumer staples and selective semiconductor opportunities.

IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%

ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.

Are Medical Stocks Lagging  Halozyme Therapeutics (HALO) This Year?

Here is how Halozyme Therapeutics (HALO) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours.

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price...

U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of Advanced Head and Neck Cancer

U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of Advanced Head and Neck Cancer U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for...

HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute

Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus.

• Reported GAAP EPS of $2.39 up 38.95% YoY
• Reported revenue of $492.97M up 39.15% YoY

Halozyme reported higher operating expenses; its disclosed risks include payer pricing and access pressures, partner milestone variability, and modest price erosion on earlier-launched ENHANZE products.

Halozymes royalties and product sales increased alongside partner-product uptake and bulk rHuPH20 demand; in October 2026, TECENTRIQ received FDA approval for its twelfth U.S. indication.

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Halozyme Therapeutics Inc.

These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 Months

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Natera reported second-quarter revenue of $752.8 million, well above Wall Street estimates of $661.3 million, according to Fiscal.ai.</li><li>BTIG raised its price target on NTRA to $320 from $290, while JPMorgan increased its target to $360 from $315.</li><li>Leerink upgraded Halozyme Therapeutics stock to ‘Outperform’ from ‘Market Perform’ and raised its price target to $110 from $83, according to TheFly.</li></ul>Shares of Natera (NTRA) and Halozyme Therapeutics (HALO) hit fresh 52-week highs on Friday, with NTRA recording its biggest single-day gains since November 2024, after analysts raised their price targets on the stock, following better-than-expected second-quarter results.At the time of writing, <a href="https://stocktwits.com/symbol/NTRA">NTRA shares</a> traded 19.2% higher, having hit an intraday high of $322, while <a href="https://stocktwits.com/symbol/HALO">HALO stock</a> was up 17.6%, after hitting an intraday high of $100.7.<h2 class="st-heading-2">Natera Raises FY2026 Revenue Outlook</h2>Natera’s second-quarter earnings beat and increased full-year 2026 revenue outlook were followed by price target raises by BTIG and JPMorgan on Friday.Natera reported second-quarter revenue of $752.8 million, up 37.7% from a year earlier and well above Wall Street estimates of $661.3 million, according to Fiscal.ai. The company reported a net loss of $0.47 per share, narrower than consensus estimates of a loss of $0.51 per share.The company also raised its 2026 revenue guidance to $2.85 billion to $2.91 billion, up from its previous forecast of $2.74 billion to $2.82 billion.BTIG raised its price target to $320 from $290, citing strong revenue growth, record Signatera testing volumes and higher guidance. Signatera is Natera’s proprietary testing method to analyze tumors.JPMorgan increased its target to $360 from $315, calling it an “exceptional” quarter for Signatera and adding that the company’s long-term growth opportunities remain underappreciated.Retail sentiment surrounding NTRA on Stocktwits changed to ‘neutral’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes. The stock has gained more than 28% so far in 2026.<h2 class="st-heading-2">Wall Street Bets On&nbsp;Halozyme’s Drug Delivery Technology</h2>Following better-than-expected second-quarter earnings, Leerink upgraded Halozyme Therapeutics stock to ‘Outperform’ from ‘Market Perform’ and raised its price target to $110 from $83, according to The Fly.On Thursday, Halozyme posted a 48% jump in Q2 revenue to $481 million, well above Wall Street estimates of $402.3 million, according to Fiscal.ai. Royalty revenue came in at $307.7 million, while earnings of $2.28 per share also beat analysts' expectations of $1.82.Leerink said recent licensing deals for its patented drug delivery technology Enhanze reinforce its view that drugmakers are unlikely to develop competing technologies in-house after patent expiration in 2029.Separately, Wells Fargo raised its price target to $95 from $75, saying higher royalty revenue from Ocrevus' subcutaneous rollout and upcoming Enhanze launches provide additional room for growth.Retail sentiment surrounding HALO on Stocktwits flipped to ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes. The stock has gained more than 43% so far this year.Also read: <a href="https://stocktwits.com/news-articles/default/equity/rdw-stock-gains-more-than-55-in-record-breaking-week-here-s-everything-that-drove-the-super-run/cZoffIDRJ9Z">RDW Stock Gains More Than 55% In Record-Breaking Week – Here’s Everything That Drove The Super Run</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Top 5 trending stocks retail is focused on now

Natera and Halozyme Therapeutics saw gains above 15%, led by bullish Wall Street commentary after better-than-expected second-quarter results.

Natera Inc

Nvidia ($NVDA) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits

) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Current Price	$100.67
Prev Close	$101.68
Open	$101.58
Dividend Yield	0.00%
50-Day Moving Average	$114.77
Beta	0.67
Avg. Volume	2.14M
PE Ratio	25.62

52-Week High	$134.00
52-Week Low	$61.23
Market Capitalization	$11.59B
EPS (Annual)	$2.56
Price to Book	-207.64
Revenue Per Employee	$3.3M

Feed

News

Sentiment

Earnings

Fundamentals

Info

HALO Fundamentals